In Vitro and In Vivo Anti-Cancer Activity Assessment, X-ray Single-Crystal Analysis, and Synthesis of Strong Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer
Keywords:
indole, hydrazone, MCF7, anticancer, apoptosis, kinase inhibitionAbstract
According to statistics from the World Health Organisation (WHO), 2.3 million women worldwide were diagnosed with
breast cancer in 2020; 685,000 of these cases ended in death.In the continuous fight against breast cancer, it is critical to investigate
innovative approaches as the disease's incidence numbers continue to grow. As a result, ethyl 3-formyl-1H-indole-2-carboxylate 1 was
reacted with thiosemicarbazide and semicarbazide to create a variety of novel indolyl-hydrazones.The new hit compounds were
obtained by combining HCl, 4-nitrophenylhydrazine, 2-dinitrophenylhydrazine, and 4-amino-5-(1H-indol-2-yl)-1,2,4-triazole-3-
thione. By using NMR, elemental analysis, and X-ray single-crystal analysis, these compounds were given chemical structures
asthiosemicarbazone3, bis(hydrazinederivative)5, semicarbzone6, Schiff base 8, and the corresponding hydrazones 10 and 12.The
compounds' cytotoxicity against breast cancer cells (MCF-7) was examined using the MTT test.In contrast to staurosproine (IC50 =
8.32±0.43μM), cytotoxicity data showed strong IC50 values against MCF-7, particularly compounds 5, 8, and 12, with IC50 values of
2.73±0.14, 4.38±0.23, and 7.03±0.37μM, respectively. Thus, the wound-healing test was used to examine the activities of compounds
5, 8, and 12 in connection to cell migration. With corresponding percentages of wound closure recorded at 48.8%, 60.7%, and 51.8%,
the results demonstrated noteworthy wound-healing effectiveness.By looking at the compounds' ability to induce apoptosis, the effect
of the hit compounds on proliferation was evaluated. Remarkably, compound 5 significantly increased cell death in MCF-7 cells,
showing a noteworthy 39.26% increase compared to the untreated control group, which showed just 1.27% cell death. Additionally,
compound 5's mode of action was examined by testing it against kinase receptors. When compared to conventional medications that
target these receptors, the findings showed promising efficacy and considerable kinase inhibition, especially against PI3K-α, PI3K-β,
PI3K-δ, CDK2, AKT-1, and EGFR. Using an in vivo experiment, compound 5 showed a significant decrease in tumour volume in the
concluding phase, going from 106 mm3 in the untreated control to 56.4 mm3. Additionally, it greatly reduced tumour growth by
46.9%. Because they successfully prevent both cell migration and proliferation, the found leads show promise for possible
development into future drugs for the treatment of breast cancer in light of these results
References
Ye,F.;Dewanjee,S.;Li,Y.;Jha,N.K.;Chen,Z.-S.;Kumar,A.;Vishakha;Behl,T.;Jha,S.K.;Tang,H.Advancementsinclinical aspectsoftargetedtherapyandimmunotherapyinbreastcancer. Mol.Cancer2023,22,105. [CrossRef][PubMed]
Senapati,S.;Mahanta,A.K.;Kumar,S.;Maiti,P.Controlleddrugdeliveryvehiclesforcancertreatmentandtheirperformance. SignalTransduct.Target.Ther.2018,3, 7.[CrossRef] [PubMed]
Ward,R.A.;Goldberg,F.W.IntroductiontoKinaseDrugDiscovery:ModernApproaches;RoyalSocietyofChemistry: London,UK, 2018; Volume 67.
Zhao,Z.;Bourne,P.E.Progresswithcovalentsmall-moleculekinaseinhibitors.DrugDiscov.Today2018,23,727–735.[CrossRef]
Bhanumathy, K.K.; Balagopal, A.; Vizeacoumar, F.S.; Vizeacoumar, F.J.; Freywald, A.; Giambra, V. Protein Tyrosine Kinases:Theirroles and their targeting in leukemia. Cancers2021, 13, 184. [CrossRef]
Patterson, H.; Nibbs, R.; McInnes, I.; Siebert, S. Protein kinase inhibitors in the treatment of inflammatory and autoimmunediseases. Clin. Exp. Immunol. 2014, 176, 1–10. [CrossRef]
Bhullar,K.S.;Lagarón,N.O.;McGowan,E.M.;Parmar,I.;Jha,A.;Hubbard,B.P.;Rupasinghe,H.P.V.Kinase-targetedcancer therapies: Progress,challengesandfuturedirections. Mol. Cancer2018,17,48. [CrossRef]
Bononi,A.;Agnoletto,C.;DeMarchi,E.;Marchi,S.;Patergnani,S.;Bonora,M.;Giorgi,C.;Missiroli,S.;Poletti,F.;Rimessi,A.; etal. Proteinkinasesandphosphatasesinthecontrolofcellfate. Enzym.Res.2011,2011,329098. [CrossRef]
Valdespino-Gómez,V.M.;Valdespino-Castillo, P.M.;Valdespino-Castillo, V.E. Cell signaling pathways interaction in cellularproliferation:Potentialtargetfortherapeuticinterventionism.CirugíaCir.2015,83,165–174.[CrossRef][PubMed]
Zhong, L.; Li, Y.; Xiong, L.; Wang, W.; Wu, M.; Yuan, T.; Yang, W.; Tian, C.; Miao, Z.; Wang, T.; et al.Small molecules in targeted cancertherapy:Advances,challenges,andfutureperspectives.Signal Transduct.Target.Ther.2021,6,201.[CrossRef][PubMed]
You, K.S.; Yi, Y.W.; Cho, J.; Park, J.S.; Seong, Y.S. Potentiating therapeutic effects of epidermal growth factor receptor inhibition intriple-negative breast cancer. Pharmaceuticals 2021, 14, 589. [CrossRef] [PubMed]
Roskoski,R.,Jr.PropertiesofFDA-approvedsmallmoleculeproteinkinaseinhibitors:A2021update.Pharmacol.Res.2021,165, 105463.[CrossRef]
Spanò, V.; Barreca, M.; Rocca, R.; Bortolozzi, R.; Bai, R.; Carbone, A.; Raimondi, M.V.; Piccionello, A.P.; Montalbano, A.; Alcaro,S.; et al.Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors.Eur. J.Med. Chem.2021, 212, 113122. [CrossRef] [PubMed]
Ostacolo, C.; Di Sarno, V.; Lauro, G.; Pepe, G.; Musella, S.; Ciaglia, T.; Vestuto, V.; Autore, G.; Bifulco, G.; Marzocco, S.; et al. Identification of an indolbased multi-target kinase inhibitor through phenotype screening and tar-get fishing using inverse virtualscreeningapproach. Eur. J.Med. Chem. 2019,167,61–75. [CrossRef][PubMed]
Kryshchyshyn-Dylevych, A.; Radko, L.; Finiuk, N.; Garazd, M.; Kashchak, N.; Posyniak, A.; Niemczuk, K.; Stoika, R.; Lesyk, R. Synthesis of novel indolethiazolidinone hybrid structures as promising scaffold with anticancer potential. Bioorganic Med. Chem. 2021, 50, 116453. [CrossRef] [PubMed]
Wang, G.; He, M.; Liu, W.; Fan, M.; Li, Y.; Peng, Z.Design, synthesisandbiologicalevaluationofnovel2-phenyl-4,5,6,7-tetrahydro- 1H- indole derivatives as potential anticancer agents and tubulin polymerization inhibitors.Arab. J.Chem.2022, 15, 103504. [CrossRef]
Ponnam, D.; Arigari, N.K.; Kalvagunta Venkata Naga, S.S.; Jonnala, K.K.; Singh, S.; Meena, A.; Misra, P.; Luqman, S. Synthesis of non-toxic anticancer active forskolin-indole-triazole conjugates along with their in silico succinate dehydrogenase inhibition studies.J.Heterocycl.Chem.2021,58,2090– 2101. [CrossRef]
Saruengkhanphasit,R.;Butkinaree,C.;Ornnork,N.;Lirdprapamongkol,K.;Niwetmarin,W.;Svasti,J.;Ruchirawat,S.;Eurtivong, C.Identificationofnew3-phenyl-1H-indole-2-carbohydrazidederivativesandtheirstructure-activityrelationshipsaspotent tubulininhibitorsandanticanceragents:Acombinedinsilico,invitroandsyntheticstudy.BioorganicChem.2021,110,104795. [CrossRef]
Hu, H.; Wu, J.; Ao, M.; Zhou, X.; Li, B.; Cui, Z.; Wu, T.; Wang, L.; Xue, Y.; Wu, Z.; et al.Design, synthesis and biological evaluation of methylenehydrazine-1- carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: NovelpotentialCDK9inhibitors. BioorganicChem. 2020,102,104064. [CrossRef]
Al-Warhi, T.; El Kerdawy, A.M.; Aljaeed, N.; Ismael, O.E.; Ayyad, R.R.; Eldehna, W.M.; Abdel-Aziz, H.A.; Al-Ansary, G.H.Synthesis, biological evaluation and in silico studies of certain oxindole–indole conjugates as anticancer CDK inhibitors. Molecules 2020, 25, 2031. [CrossRef]
Zhao,P.;Li,Y.;Gao,G.;Wang,S.;Yan,Y.;Zhan,X.;Liu,Z.;Mao,Z.;Chen,S.;Wang,L.Design,synthesisandbiologicalevaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual Cyclin-Dependent Kinase 2 (CDK2)/Glycogen Synthase Kinase3β(GSK-3β)phosphorylationinhibitors. Eur.J.Med.Chem.2014,86,165–174. [CrossRef]
Oudard,S.;Beuselinck,B.;Decoene,J.;Albers,P.Sunitinibforthetreatmentofmetastaticrenalcellcarcinoma.CancerTreat.Rev. 2011,37,178–184.[CrossRef] 18–31. [CrossRef]
Gridelli, C.; Maione, P.; Del Gaizo, F.; Colantuoni, G.; Guerriero, C.; Ferrara, C.; Nicolella, D.; Comunale, D.; De Vita, A.; Rossi, A. Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer.Oncologist2007, 12, 191–200. [CrossRef] [PubMed]
Imming,P.;Sinning,C.;Meyer,A.Drugs,theirtargetsandthenatureandnumberofdrugtargets.Nat.Rev.DrugDiscov. 2006,5,821–834.[CrossRef] [PubMed]
Lockhart, A.C.; Cropp, G.F.; Berlin, J.D.; Donnelly, E.; Schumaker, R.D.; Schaaf, L.J.; Hande, K.R.; Fleischer, A.C.; Hannah, A.L.; Rothenberg, M.L. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients withmetastaticcolorectalcancer. Am.J.Clin.Oncol.2006,29,109–115. [CrossRef][PubMed]
Boraei,A.T.A.;Gomaa,M.S.;ElAshry,E.S.H.;Duerkop,A.Design,selectivealkylationandX-raycrystalstructuredetermination of dihydro-indolyl-1,2,4- triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents.Eur. J.Med.Chem. 2017, 125, 360–371. [CrossRef] [PubMed]
Boraei, A.T.A.; Singh, P.K.; Sechi, M.; Satta, S. Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design,synthesisandantitumoractivityevaluation. Eur.J.Med.Chem.2019,182,111621. [CrossRef][PubMed]
Mohamady, S.; Galal, M.; Eldehna, W.M.; Gutierrez, D.C.; Ibrahim, H.S.; Elmazar, M.M.; Ali, H.I. Dual Targeting of VEGFR2 andC-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as AngiogenesisInhibitors.ACSOmega2020,5,18872– 18886.[CrossRef]
Al-Hussain, S.A.; Farghaly, T.A.; Zaki, M.E.A.; Abdulwahab, H.G.; Al-Qurashi, N.T.; Muhammad, Z.A. Discovery of novel indolyl- 1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal canceractivity. BioorganicChem.2020,105,104330. [CrossRef]
Nafie, M.S.; Boraei, A.T.A. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyltriazoleSchiffbasesfortargetingbreastcancer.Bioorg.Chem.2022,122,105708.[CrossRef]
Lee, D.H.; Szczepanski, M.J.; Lee, Y.J. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in humanprostatecancercells. J.Cell.Biochem.2009,106,1113–1122. [CrossRef][PubMed]
Sreenivasulu, R.; Reddy, K.T.; Sujitha, P.; Kumar, C.G.; Raju, R.R. Synthesis, antiproliferative and apoptosis induction potentialactivitiesofnovelbis(indolyl)hydrazide-hydrazonederivatives.Bioorg.Med.Chem.2019,27,1043–1055.[CrossRef][PubMed]
Das Mukherjee, D.; Kumar, N.M.; Tantak, M.P.; Das, A.; Ganguli, A.; Datta, S.; Kumar, D.; Chakrabarti, G. Development of novel bis(indolyl)-hydrazide– hydrazonederivativesaspotentmicrotubule-targetingcytotoxicagentsagainstA549lungcancercells. Biochemistry2016,55,3020–3035. [CrossRef][PubMed]
Kilic-Kurt, Z.; Acar, C.; Ergul, M.; Bakar-Ates, F.; Altuntas, T.G. Novel indole hydrazide derivatives:Synthesis and their antiproliferativeactivitiesthroughinducingapoptosisandDNAdamage. Arch. Pharm. 2020,353,2000059. [CrossRef]
RikaguOxfordDiffraction.CrysAlisPro;RikaguOxfordDiffractionInc.:Yarnton,UK,2020.
Sheldrick,G.M.SHELXT–Integratedspace-groupandcrystal-structuredetermination.ActaCryst.2015,A71,3–8.[CrossRef]
Hübschle,C.B.;Sheldrick,G.M.;Dittrich,B.ShelXle:AQtgraphicaluserinterfaceforSHELXL.J.Appl.Crystallogr. 2011,44,1281–1284.[CrossRef]
VanMeerloo,J.; Kaspers,G.J.L.; Cloos,J.Cell SensitivityAssays:TheMTT Assay.MethodsMol.Biol.2011, 731,237–245.
Mohamed,F.A.M.;Gomaa,H.A.M.;Hendawy,O.M.;Ali,A.T.;Farghaly,H.S.;Gouda,A.M.;Abdelazeem,A.H.;Abdelrahman, M.H.;Trembleau,L.;Youssif,B.G.M.Design,Synthesis,andBiologicalEvaluationofNovelEGFRInhibitorsContaining5-Chloro-3-Hydroxymethyl-Indole-2- Carboxamide Scaffold with Apoptotic Antiproliferative Activity. Bioorganic Chem. 2021, 112, 104960.[CrossRef]
Ali, G.M.E.; Ibrahim, D.A.; Elmetwali, A.M.; Ismail, N.S.M. Design, Synthesis and Biological Evaluation of Certain CDK2 InhibitorsBasedonPyrazoleandPyrazolo[1,5-a]PyrimidineScaffoldwithApoptoticActivity. BioorganicChem.2019,86,1–14. [CrossRef]
Qin, X.; Han, X.; Hu, L.; Li, Z.; Geng, Z.; Wang, Z.; Zeng, C.; Xiao, X. Design, Synthesis and Biological Evaluation of Quinoxalin- 2(1H)- OneDerivativesasEGFRTyrosineKinaseInhibitors.Anticancer.AgentsMed.Chem.2015,15,267–273.[CrossRef]
AkgÜl,Ö.;ErdoG˘an,M.A.;BI˙rI˙m,D.;KayabaS¸i,Ç.;GÜndÜz, C.;A rmaG˘an, G.Design,Synthesis, CytotoxicActivity,and ApoptosisInducingEffectsof4-andN-SubstitutedBenzoyltaurinamideDerivatives.Turk.J.Chem.2020,44,1674–1693.[CrossRef]
Turner, D.P.; Moussa, O.; Sauane, M.; Fisher, P.B.; Watson, D.K. Prostate-derived ETS factor is a mediator of metastatic potentialthrough the inhibition of migration and invasion in breast cancer.Cancer Res. 2007, 67, 1618–1625.[CrossRef]
Chen, Y.; Lu, B.; Yang, Q.; Fearns, C.; Yates, J.R.; Lee, J.-D. Combined Integrin Phosphoproteomic Analyses and siRNA-based Functional Screening Identified Key Regulators for Cancer Cell Adhesion and Migration.Cancer Res.2009,69, 3713–3720. [CrossRef] [PubMed]
Barghash,R.F.;Eldehna,W.M.;Kovalová,M.;Vojácˇková,V.;Kryštof,V.;Abdel-Aziz,H.A.One-PotThree-ComponentSynthesis ofNovelPyrazolo[3,4- b]PyridinesasPotentAntileukemicAgents. Eur. J.Med. Chem. 2022,227,113952. [CrossRef]
Noser,A.A.;Abdelmonsef,A.H.;Salem,M.M.Design,SynthesisandMolecularDockingofNovelSubstitutedAzepinesas InhibitorsofPI3K/Akt/TSC2/mTORSignalingPathwayinColorectalCarcinoma.Bioorganic Chem.2023,131,106299.[CrossRef]
Lapillo, M.; Tuccinardi, T.; Martinelli, A.; Macchia, M.; Giordano, A.; Poli, G. Extensive Reliability Evaluation of Docking-Based Target- FishingStrategies. Int. J.Mol. Sci. 2019,20,1023. [CrossRef][PubMed]
Dhanalakshmi, B.; Anil Kumar, B.M.; Srinivasa Murthy, V.; Srinivasa, S.M.; Vivek, H.K.; Sennappan, M.; Rangappa, S. Design, Synthesis and Docking Studies of Novel 4-Aminophenol-1,2,4-Oxadiazole Hybrids as Apoptosis Inducers against Triple Negative Breast Cancer Cells Targeting MAP Kinase. J.Biomol. Struct. Dyn. 2023, 1–17. [CrossRef] [PubMed]
Dicato,M.;Plawny,L.;Diederich,M.Anemiaincancer.Ann.Oncol.2010,21,vii167–vii172.[CrossRef]
HEl Zahabi, S.A.; Nafie, M.S.; Osman, D.; Elghazawy, N.H.; Soliman, D.H.; EL-Helby, A.A.H.; Arafa, R.K. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity.Eur. J.Med. Chem. 2021,222,113609.
Boraei, A.T.A.; Eltamany, E.H.; Ali, I.A.I.; Gebriel, S.M.; Nafie, M.S. Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: Invitro, invivo, and in silico integrated approaches.Bioorganic Chem. 2021, 111, 104877. [CrossRef]
